Lung nodules seen in a high percentage of non-smokers

Published Date: 14 Aug 2024

A new study of more than 10,000 non-smoking adults found that solid lung nodules were present in a considerable portion of study participants. Non-smokers are traditionally thought to be at low risk for lung nodules and lung ...

Read Full News

Todays Updates


Q&A: Mucus Plugging, Multimorbidity, and GOLD 2027, With Gerard Criner, MD


Q&A: Mucus Plugging, Multimorbidity, and GOLD 2027, With Gerard Criner, MD

RENEW: Blinded Interim Data Show FVC Trends With LTI-03 in IPF


RENEW: Blinded Interim Data Show FVC Trends With LTI-03 in IPF

Anaphylaxis Reporting Varies Across Respiratory Biologics In FAERS


Anaphylaxis Reporting Varies Across Respiratory Biologics In FAERS

Navigating a New Era of Neuromuscular Drug Development and Care at MDA 2027 Angela Lek, PhD, Isabella Ciccone, MPH


Angela Lek, PhD, chief research officer at the Muscular Dystrophy Association, discussed how the 2027 MDA Clinical and Scientific Conference agenda reflects key themes in neuromuscular medicine.

Spectris Misses Primary End Point in Pivotal HOPE Trial for Alzheimer Disease Isabella Ciccone, MPH


In the prespecified mild subgroup of HOPE, 40-Hz gamma sensory stimulation was associated with 56% slowing on the ADCS-ADL and 47% slowing on the CDR-SB vs sham at 12 months.

Full X-TOLE2 Data Detail Azetukalner's Dose-Dependent Profile in Focal Epilepsy Marco Meglio


Peer-reviewed results from the phase 3 X-TOLE2 trial, published in JAMA Neurology, detail azetukalner's seizure reduction and dose-dependent adverse events in adults with focal epilepsy.

FDA Approves Adrabetadex as First Therapy Shown to Improve Survival in Infantile-Onset Niemann-Pick Disease Type C Isabella Ciccone, MPH


The FDA approved Beren Therapeutics' adrabetadex, marketed as Lembaz, to reduce the risk of death in patients with infantile-onset Niemann-Pick disease type C.

Todays Updates


Q&A: Mucus Plugging, Multimorbidity, and GOLD 2027, With Gerard Criner, MD


Q&A: Mucus Plugging, Multimorbidity, and GOLD 2027, With Gerard Criner, MD

RENEW: Blinded Interim Data Show FVC Trends With LTI-03 in IPF


RENEW: Blinded Interim Data Show FVC Trends With LTI-03 in IPF

Anaphylaxis Reporting Varies Across Respiratory Biologics In FAERS


Anaphylaxis Reporting Varies Across Respiratory Biologics In FAERS

Navigating a New Era of Neuromuscular Drug Development and Care at MDA 2027 Angela Lek, PhD, Isabella Ciccone, MPH


Angela Lek, PhD, chief research officer at the Muscular Dystrophy Association, discussed how the 2027 MDA Clinical and Scientific Conference agenda reflects key themes in neuromuscular medicine.

Spectris Misses Primary End Point in Pivotal HOPE Trial for Alzheimer Disease Isabella Ciccone, MPH


In the prespecified mild subgroup of HOPE, 40-Hz gamma sensory stimulation was associated with 56% slowing on the ADCS-ADL and 47% slowing on the CDR-SB vs sham at 12 months.

Full X-TOLE2 Data Detail Azetukalner's Dose-Dependent Profile in Focal Epilepsy Marco Meglio


Peer-reviewed results from the phase 3 X-TOLE2 trial, published in JAMA Neurology, detail azetukalner's seizure reduction and dose-dependent adverse events in adults with focal epilepsy.

FDA Approves Adrabetadex as First Therapy Shown to Improve Survival in Infantile-Onset Niemann-Pick Disease Type C Isabella Ciccone, MPH


The FDA approved Beren Therapeutics' adrabetadex, marketed as Lembaz, to reduce the risk of death in patients with infantile-onset Niemann-Pick disease type C.

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Skipping Lymph Node Biopsy Gains Ground in Breast Cancer

2.

Research has shown that Ga-68 FAPI PET enhances pancreatic cancer detection and staging.

3.

New tumor therapy approach reduces costs and side effects while increasing accessibility

4.

Temsirolimus Plus Chemotherapy Fails in Rare Childhood Cancer

5.

Alone for 500 Days, but Never Lonely: The Introvert's Dream.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot